Taranabant

Drugbox
IUPAC_name = N- [(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl] -2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide

---

CAS_number = 701977-09-5
ATC_prefix = A08
ATC_suffix = AX
PubChem =
DrugBank =
chemical_formula = |C=27|H=25|Cl=1|F=3|N=3|O=2
molecular_weight = 515.95
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral

Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 inverse agonist being investigated as a potential treatment for obesity due to its anorectic effects. [Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK, et al. "Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists." "Bioorganic & Medicinal Chemistry Letters". 2007 Apr 15;17(8):2184-7. PMID 17293109. doi|10.1016/j.bmcl.2007.01.087] [Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. "Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N- [(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl] -2-methyl-2- [5-(trifluoromethyl)pyridin-2-yl] oxy] propanamide (MK-0364), in rodents." "Journal of Pharmacology and Experimental Therapeutics". 2007 Jun;321(3):1013-22. PMID 17327489. doi|10.1124/jpet.106.118737] It was discovered by Merck & Co.

In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central side effects, mainly depression and anxiety.cite web |url=http://www.merck.com/newsroom/press_releases/research_and_development/2008_1002.html |title=Press release by Merck |format= |work= |accessdate=October 2008]

References